Skip to main content

Givosiran Side Effects

Medically reviewed by Last updated on Aug 13, 2023.

Applies to givosiran: subcutaneous solution.

Serious side effects of Givosiran

Along with its needed effects, givosiran may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking givosiran:

More common


Other side effects of Givosiran

Some side effects of givosiran may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to givosiran: subcutaneous solution.


The most commonly reported adverse reactions included nausea and injection site reactions.[Ref]


Uncommon (0.1% to 1%): Anaphylactic reaction, hypersensitivity

In clinical trials, 1 patient experienced an anaphylactic reaction and 1 patient experienced a hypersensitivity reaction.


Very common (10% or more): Transaminase elevations (13%)


Very common (10% or more): Increase serum creatinine (15%; includes blood creatinine increased, glomerular filtration rate decreased, chronic kidney disease [decreased eGFR])


Very common (10% or more): Injection site reactions (25%)


Very common (10% or more): Nausea (27%)


Very common (10% or more): Rash (17%; includes pruritus, eczema, erythema, rash, pruritic rash, urticaria)


As with all oligonucleotides, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and therefore comparison of antibody incidence is misleading. In placebo-controlled and open-label clinical studies, 1 of 111 patients with acute hepatic porphyria (AHP;0.9%) developed treatment-emergent anti-drug antibodies (ADA) during treatment. No clinically significant differences in the clinical efficacy, safety, pharmacokinetic, or pharmacodynamic were observed in the patients who tested positive for ADA.

Uncommon (0.1% to 1%): Treatment emergent anti-drug antibodies


Very common (10% or more): Fatigue (10%)


1. Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.